secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001104659-22-091217
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics appoints Dr. Julia A. Haller to board, increases size to 10
--------------------------------------------------------------------------------

- Board expanded from 9 to 10 members; Dr. Haller appointed as Class II director effective Aug 11, 2022.
- Dr. Haller replaces Randy Thurman on Nominating and Corporate Governance Committee; Thurman stays on board.
- Received option for 25,000 shares at $1.15 (Aug 11 close), vesting over 3 years under 2015 Equity Incentive Plan.
- Standard indemnification agreement entered; compensation per non-employee director policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465922091217/0001104659-22-091217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465922091217/tm2223402d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-091217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer